1. Home
  2. EMF vs IPHA Comparison

EMF vs IPHA Comparison

Compare EMF & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$23.01

Market Cap

253.7M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.84

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMF
IPHA
Founded
1987
1999
Country
United States
France
Employees
N/A
163
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.7M
189.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EMF
IPHA
Price
$23.01
$1.84
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
37.3K
9.5K
Earning Date
01-01-0001
03-26-2026
Dividend Yield
6.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.10
$1.18
52 Week High
$24.70
$2.63

Technical Indicators

Market Signals
Indicator
EMF
IPHA
Relative Strength Index (RSI) 48.64 54.67
Support Level $21.48 $1.73
Resistance Level $24.53 $1.97
Average True Range (ATR) 0.83 0.09
MACD -0.17 -0.00
Stochastic Oscillator 26.71 50.57

Price Performance

Historical Comparison
EMF
IPHA

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: